Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > GOPIVEO & LEMBAYLI

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 06, 2021 11:46am

189 Views

Post# 34202334

RE:RE:GOPIVEO & LEMBAYLI

Seemyvest wrote: Hey. Thanks for posting. I have no idea what this would mean? Any thoughts?

Prior to the AME pause, we know ATE was working with an outside pharma marketing firm(s) to find a name(s) for OTENAPROXESUL. I think that's normal course of business with respect to bringing drugs to market. The drug wouldn't be marketed as OTENA but some branded name chosen by the company - or different names in dfferent parts of the world.

I'm assuming it's related to that.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?